65,437 trials
Idiopathic Short Stature
Primary: Change From Baseline in Height Velocity at Month 6 Using Last Observation Carried Forward (LOCF) Method — 5.63; 4.94; 4.45; 1.01 centimeter/year (cm/yr) — p=<0.0001
Hereditary Angioedema
Primary: Time to Complete or Near Complete Resolution From Onset of Symptoms — 735; 377 minutes
Head and Neck Neoplasms
Primary: Opreation Duration — 97.1; 116.3 minutes — p=0.022
Colorectal Cancer
Primary: Safety: Number of Participants With Serious and Specific Adverse Events — 50; 57; 42; 22 participants
Healthy Volunteer
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Alectinib — 3990; 1020 ng*hour/mL
Rheumatoid Arthritis
Primary: Percentage of Participants on Tocilizumab Treatment at 6 Months After Treatment Initiation — 84 percentage of participants
Coronary Artery Disease · Acute Coronary Syndrome
Primary: Platelet Reactivity Measured as P2Y12 Reaction Units (PRU) Determined by Verify Now-P2Y12 Assay — 45; 63 PRU
Kidney Disease · Albuminuria
Primary: The Primary Outcome Measure is Level of Albuminuria. — 927.9; 897.1 ratio
Type 1 Diabetes · Preservation of Insulin Secretion · Newly Diagnosed Type 1 Diabetes
Primary: C-peptide Response to Mixed Meal Glucose Tolerance Test (MMTT) at One Year for Subjects Given Canakinumab Compared to Placebo — 0.40; 0.41 nmol/L — p=0.86
Breast Cancer
Primary: Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD) Total and Subscale Score at Baseline — 88.9; 28.0; 21.9; 19.1 units on a scale
Diabetes Mellitus · Coronary Artery Disease
Primary: P2Y12 Reaction Units — 83; 52 PRU — p=0.022
Bipolar Disorder · Cocaine Dependence
Primary: Change From Baseline in Percentage of Cocaine-abstinent Days — 16.4; 14.5 percentage of days cocaine abstinent
Melanoma
Primary: Best Objective Response Rate (BORR) — 24 percentage of patients
Hereditary Tyrosinemia, Type I
Primary: Maximum Observed Plasma Concentration (Cmax) — 1277.77; 1272.34; 1339.79 ng/mL
Mitral Valve or Aortic Valve Replacement
Primary: The Performance Evaluation of Perimount Heart Valve(Type:6900P and 2900) by Echocardiography — 100; 54.54; 26.51; 81.33 Percentage of all subjects